Qiagen stock gains after Morgan Stanley lifts price target
Published on 09/16/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Qiagen N.V. stock (ISIN NL0012169213) ended the last completed trading day on the New York Stock Exchange at 41.84 dollars on September 14, 2026, down 1.55 percent from its previous close as investors digested fresh analyst commentary and recent guidance signals for the diagnostics group.
Analyst support lifts Qiagen stock
According to Ad-hoc-news.de, Qiagen stock on Xetra closed at 36.91 euros on September 14, 2026, which was 1.05 percent above the prior close of 36.53 euros and came with an intraday range between roughly 36.53 and 37.06 euros.
In the same report published on September 16, 2026, Ad-hoc-news.de noted that Morgan Stanley lifted its price target for Qiagen and issued a buy signal on the shares, a combination that helped attract fresh investor interest and provided a positive backdrop for the stock.
Q2 revenue outlook and Q3 caution frame fundamentals
As MarketWatch reported in an article last updated on September 13, 2026, Qiagen recently provided an upbeat second-quarter revenue outlook, which supported the stock intraday before a more cautious view on third-quarter prospects led to a 4.5 percent decline from earlier session levels.
The MarketWatch report states that shares of Qiagen climbed as much as 1.7 percent intraday before reversing lower, underscoring how investors welcomed the stronger second-quarter revenue guidance but reacted more skeptically to the outlook for the subsequent quarter, where management flagged a downbeat picture compared with the momentum seen earlier in the year.
While detailed revenue and earnings figures for the most recent quarter are not fully listed in the available snippets, the combination of an improved second-quarter revenue outlook and a softer third-quarter view marks a clear quantified contrast in the company’s near-term growth profile and helps explain the mixed share-price reaction described by MarketWatch.
NYSE price, valuation and Xetra comparison
Per the NYSE quote overview on MarketBeat, Qiagen stock closed at 41.84 dollars on September 14, 2026, at 3:59 p.m. Eastern, which represented a decline of 0.66 dollars or 1.55 percent versus the prior closing price and left the shares modestly below their recent trading range highs.
The same MarketBeat snapshot shows that in extended trading on September 15, 2026, Qiagen shares traded at 41.97 dollars, 0.31 percent above the official close, indicating a slight recovery in after-hours activity that mirrors the more constructive stance from Morgan Stanley reported by Ad-hoc-news.de.
Comparing the NYSE closing price of 41.84 dollars on September 14, 2026 with the Xetra close of 36.91 euros on the same date highlights a small valuation gap between the United States listing and the home-market quotation, although currency effects and trading-hub dynamics mean investors should consider both venues separately when assessing performance.
Closing price context for Qiagen stock
Qiagen stock thus stands at 41.84 dollars on the NYSE as of September 14, 2026, with a daily loss of 1.55 percent, while the parallel Xetra quote at 36.91 euros showed a 1.05 percent gain on the same day; the divergence between the two venues underlines how analyst support and differing investor bases can create short-term variations in performance even for the same underlying company.
Qiagen stock key data
- Company: Qiagen N.V.
- ISIN: NL0012169213
- Ticker: QGEN
- Trading venue: NYSE
- Price (as of September 14, 2026, 15:59): 41.84 USD
- Market capitalization: [value not specified in available sources] USD (as of September 14, 2026)
- Sector / Industry: Life sciences tools and diagnostics
- Index membership: TecDAX
